CA2254121A1 - Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2 - Google Patents

Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2 Download PDF

Info

Publication number
CA2254121A1
CA2254121A1 CA002254121A CA2254121A CA2254121A1 CA 2254121 A1 CA2254121 A1 CA 2254121A1 CA 002254121 A CA002254121 A CA 002254121A CA 2254121 A CA2254121 A CA 2254121A CA 2254121 A1 CA2254121 A1 CA 2254121A1
Authority
CA
Canada
Prior art keywords
treatment
methylsulfonyl
furanone
fluorophenyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002254121A
Other languages
English (en)
Inventor
Bruno Hancock
Conrad Winters
Barry Gertz
Keith Gottesdiener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9612065.4A external-priority patent/GB9612065D0/en
Application filed by Individual filed Critical Individual
Publication of CA2254121A1 publication Critical patent/CA2254121A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique de traitement de maladies à médiation cyclooxygénase-2, cette composition pouvant être administrée une fois par jour par voie orale et contenant de 2,5 à 250 mg de 5,5 -diméthyl-3-(3 fluorophényl)-4-(4-méthylsulfonyl)phényl)-2-(5H)-furanone. L'invention concerne également une méthode pour traiter les maladies à médiation cyclooxygénase-2 comprenant l'administration d'une dose quotidienne de 2,5 à 250 mg de 5,5 -diméthyl-3-(3 fluorophényl)-4-(4-méthylsulfonyl)phényl)-2-(5H)-furanone. L'invention concerne également une utilisation de 5,5 -diméthyl-3-(3 fluorophényl)-4-(4-méthylsulfonyl)phényl)-2-(5H)-furanone dans la production d'un médicament contenant entre 2,5 et 250 mg dudit composé à administrer à raison d'une dose quotidienne pour le traitement de maladies à médiation cyclooxygénase-2.
CA002254121A 1996-05-17 1997-05-13 Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2 Abandoned CA2254121A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1789196P 1996-05-17 1996-05-17
US60/017,891 1996-05-17
GBGB9612065.4A GB9612065D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxtgenase-2 mediated diseases
GB9612065.4 1996-06-10
PCT/US1997/007985 WO1997044027A1 (fr) 1996-05-17 1997-05-13 Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2

Publications (1)

Publication Number Publication Date
CA2254121A1 true CA2254121A1 (fr) 1997-11-27

Family

ID=26309473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002254121A Abandoned CA2254121A1 (fr) 1996-05-17 1997-05-13 Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2

Country Status (3)

Country Link
AU (1) AU3122597A (fr)
CA (1) CA2254121A1 (fr)
WO (1) WO1997044027A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1061908A4 (fr) * 1998-03-13 2007-01-24 Merck & Co Inc Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
AR030188A1 (es) * 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
AU3122597A (en) 1997-12-09
WO1997044027A1 (fr) 1997-11-27

Similar Documents

Publication Publication Date Title
US6063811A (en) Compositions for a once day treatment of cyclooxygenase-2 mediated diseases
FI114913B (fi) Menetelmä terapeuttisesti käyttökelpoisten furanonijohdannaisten valmistamiseksi ja menetelmässä käyttökelpoinen lähtöaine
FI108792B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten furanonijohdannaisten valmistamiseksi
HU227732B1 (en) Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof
GB2089660A (en) Cobalt compound-containing preparations for arthritis treatment
CA2254121A1 (fr) Compositions de traitement journalier monodose de maladies a mediation cyclooxygenase-2
JPH0140009B2 (fr)
WO1997011701A1 (fr) Compositions de traitement d'inflammations contenant certaines prostaglandines et un inhibiteur de cyclo-oxygenase-2 selectif
CA2301590C (fr) 2-aminopyridines utilisees comme inhibiteurs de la cyclo-oxygenase 2
CN109810049B (zh) 一种含吡啶的化合物及其提取方法
EP1090915B1 (fr) Forme polymorphe B de 3-(cyclopropylmethoxy)-4- -4-(méthylsulfonyl)phényl - 5,5-diméthyl-5H-furan-2-one
RU2101011C1 (ru) Средство, обладающее анальгетическим действием
AU775030B2 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
TW536404B (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CN103717586A (zh) 用于治疗糖尿病的与葡糖激酶调节蛋白相互作用的苯并二氧杂*和苯并二氧杂环己烯化合物
KR20000072005A (ko) 구연산칼륨을 주제로 한 요로결석 치료제중 분말 및 미립제형 의 제조방법
UA51706C2 (uk) Спосіб лікування запального захворювання за допомогою 3-феніл-4-(4-метилсульфоніл)феніл)-2-(5н)-фуранону
JPH0321558B2 (fr)
WO1994003183A1 (fr) Composition medicinale pour empecher que les metastases du cancer ne s'etendent au foie et composition medicinale pour soigner l'hepatome
JPS6141357B2 (fr)
ZA200307067B (en) Antiproliferative agents.
JPS6152823B2 (fr)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued